The Indiana University Cancer Center renamed Indiana University Melvin and Bren Simon Cancer Center
In 2006, The Indiana University Cancer Center was renamed the Indiana University Melvin and Bren Simon Cancer Center….
Calistoga Pharmaceuticals was founded
In 2006, Calistoga Pharmaceuticals was founded as a Seattle-based spin-off from ICOS Corp. that was dedicated to developing…
NCI and NHGRI launched effort to accelerate understanding molecular basis of cancer with genome analysis
On Dec. 13, 2005, the National Cancer Institute (NCI) and the National Human Genome Research Institute launched a…
Biotechnology | Diagnostics | Disease | Life Science News | Oncology | Therapeutics | Women's Health
Studies validated a new test can predict risk of breast cancer recurrence in a sizable group of patients
On Dec. 7, 2005, results from several studies presented at the San Antonio Breast Cancer Symposium validated that…
Biotechnology | Diagnostics | Life Science News | Non-Profit Research | Oncology | Radiology | Therapeutics
Karmanos Cancer Institute became Michigan’s first and only independent hospital exclusively for cancer patients
On Dec. 1, 2005, the Barbara Ann Karmanos Cancer Institute became Michigan’s first and only independent hospital exclusively…
Biotechnology | Diagnostics | Life Science News | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The 2-Year Extension of Postage Stamp for Breast Cancer Research (PL 109-100) was extended
On Nov. 11, 2005, the U.S. Congress authorized the 2-year extension of Postage Stamp for Breast Cancer Research…
National Cancer Institute launched a cancer biorepository pilot project to standardize biospecimen collection
On Nov. 7, 2005, the National Cancer Institute launched a cancer biorepository pilot project designed to standardize biospecimen…
Biotechnology | Diagnostics | Disease | Life Science News | NIH | Non-Profit Research | Oncology | Therapeutics
Annual Report to the Nation on the Status of Cancer showed cancer death rates dropped from 1993-2002
On Oct. 5, 2005, the National Cancer Institute’s Annual Report to the Nation on the Status of Cancer,…
Biotechnology | Diagnostics | Disease | Life Science News | Non-Profit Research | Oncology | Radiology | Therapeutics
Siteman Cancer Center opened a new center at Barnes-Jewish St Peters Hospital
On Sept. 22, 2005, the Siteman Cancer Center opened a new center at Barnes-Jewish St. Peters Hospital. The…
Preliminary results from clinical trial of digital vs. film mammography showed no difference in breast cancer detection
On Sept. 16, 2005, preliminary results from a large, clinical trial of digital vs. film mammography showed no…
The National Cancer Institute approved a $10 million award for OHSU Cancer Institute
On Jul. 18, 2005, Oregon Health & Science University (OHSU) announced receipt of a five-year, $10 million award…
Biotechnology | Diagnostics | Disease | Life Science News | Non-Profit Research | Oncology | Radiology | Therapeutics
Karmanos Cancer Institute acquired clinical facilities from the Detroit Medical Center
On May 1, 2005, The Wayne State University Karmanos Cancer Institute announced it had acquired its clinical facilities…
Biotechnology | Diagnostics | Disease | Life Science News | Oncology | Therapeutics | Women's Health
NCI-sponsored clinical trials showed patients with early-stage, HER2-positive, invasive breast cancer experienced decrease in risk of cancer recurrence
On Apr. 27, 2005, results from two large National Cancer Institute sponsored randomized clinical trials showed that patients…
NCI trial reported targeted agent trastuzumab and standard chemo cut risk of HER-2-positive breast cancer
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
Moores Cancer Center at UC San Diego opened new consolidated facility
On Apr. 8, 2005, Moores Cancer Center (MCC) at University of California, San Diego opened its new consolidated…
Biotechnology | Diagnostics | Disease | FDA | Life Science News | Nanotechnology | Oncology | Therapeutics
FDA approved albumin-stabilized nanoparticle formulation of paclitaxel for treatment of breast cancer
In Jan. 2005, the U.S. Food and Drug Administration (FDA) approved an albumin-stabilized nanoparticle formulation of paclitaxel (Abraxane)…
The Georgia Legislature passed the Smoke Free Air Act
In 2005, the Georgia Legislature passed the Smoke Free Air Act, banning indoor smoking in publicly accessible buildings,…
The National Cancer Institute study determined that a new molecular test can predict the risk of breast cancer recurrence
On Dec. 10, 2004, a National Cancer Institute (NCI) supported study determined that a new molecular test done…
Biotechnology | Disease | FDA | Life Science News | Oncology | Therapeutics
Genentech drug Tarceva (erlotinib) was approved
On Nov. 18, 2004, the U.S. Food and Drug Administration (FDA)Â announced it had approved Genentech’s drug Tarceva…
Letrozole was approved by the FDA for the adjuvant treatment of early-stage breast cancer after five years of tamoxifen therapy
On Oct. 29, 2004, the U.S. Food and Drug Administration (FDA) approved Letrozole for the extended adjuvant treatment…
Biotechnology | Diagnostics | Disease | Environmental | Life Science News | NIH | Non-Profit Research | Oncology | Therapeutics
The National Center for Vermiculite and Asbestos-Related Cancers was established
Apr. 14, 2004, the National Center for Vermiculite and Asbestos-Related Cancers was established in Michigan in response to…
Biotechnology | Diagnostics | FDA | Life Science News | NIH | Oncology
The FDA and NCI announced they will share knowledge and resources to facilitate development of new cancer drugs
On Mar. 16, 2004, the Food and Drug Administration (FDA) released a report addressing the recent slowdown in…
FDA approved the first antiangiogenic drug for cancer, Avastin
On Feb. 26, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved the first antiangiogenic…
The monoclonal antibody cetuximab (Erbitux) was approved by the FDA for the treatment of metastatic colorectal cancer
On Feb. 1, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved Cetuximab, a recombinant…
Biotechnology | Disease | FDA | Life Science News | Oncology | Therapeutics
The FDA approved oxaliplatin (Eloxatin) for use in the treatment of advanced colorectal cancer
On Jan. 9, 2004, the Food and Drug Administration (FDA) announced the approval of Sanofi’s Eloxatin (oxaliplatin) injection…
Biotechnology | Diagnostics | FDA | Life Science News | NIH | Oncology | Therapeutics
The National Cancer Institute collaborated with the Department of Health and Human Services to establish National Network of Tobacco Cessation Quitlines
In 2004, the National Cancer Institute (NCI) collaborated with the Department of Health and Human Services to establish…
Biotechnology | Diagnostics | Disease | Life Science News | Oncology | Radiology | Therapeutics | Women's Health
Women’s Health Initiative data showed women who take estrogen with hormone progestin have greater risk of developing breast cancer
In 2004, data from the Women’s Health Initiative (WHI) study show that women who take estrogen in combination…
Siteman Cancer Center was designated a Comprehensive Cancer Center by the NCI
On Jan. 20, 2005, the Siteman Cancer Center received National Cancer Institute (NCI) designation as a Comprehensive Cancer…
Biotechnology | Diagnostics | Disease | Life Science News | Medical Device | Neurology | Oncology | Therapeutics
OMRF opened the state’s first small animal magnetic resonance imaging facility
In 2004, the Oklahoma Medical Research Foundation (OMRF) opened the state’s first small animal magnetic resonance imaging facility….
Biotechnology | Diagnostics | Disease | Life Science News | Oncology | Radiology | Therapeutics | Women's Health
World’s first use of low-dose radioactive palladium ‘seeds’ was used to treat breast cancer patients at the Women’s Research Institute in Toronto.
In 2004, the world’s first use of low-dose radioactive palladium ‘seeds’ as used to treat breast cancer patients…